Justin van der Meid
Psychiatry · Aberdeen, SDNPI 1548656374
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 95 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 12 manufacturers reported payments, led by AbbVie at 37.0% of the total. 2025 is the largest year on record at $792, more than ten times the $42 reported in 2022.
Across 95 payments — averaging $15.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$556
- Neurocrine Biosciences, Inc.$210
- Alkermes, Inc.$192
- Teva Pharmaceuticals USA, Inc.$160
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$120
- Collegium Pharmaceutical, Inc.$57
- plus $210 from 6 others
What the payments were for
- Food & beverage$1,505100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$1,505 in reported general payments places this provider in the 80th percentile of 79 psychiatry providers in South Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NuedextaDextromethorphan Hbr/Quinidine | 17 | $17,722 |
| Lisdexamfetamine Dimesylate | 28 | $7,354 |
| VyvanseLisdexamfetamine Dimesylate | 17 | $6,163 |
| Methylphenidate ErMethylphenidate Hcl | 11 | $3,999 |
| Bupropion XlBupropion Hcl | 185 | $3,144 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 37 | $2,839 |
| Olanzapine | 127 | $2,708 |
| Quetiapine Fumarate | 236 | $2,554 |
| Duloxetine Hcl | 263 | $2,329 |
| Trazodone Hcl | 229 | $1,920 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 53 | $1,789 |
| Aripiprazole | 123 | $1,635 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 59 | $1,596 |
| Ziprasidone Hcl | 36 | $1,466 |
| Fluoxetine Hcl | 109 | $1,404 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Aberdeen
- Navaid KhanAberdeen$79
- Xiaolin DengAberdeen$34
- James ChiuSioux Falls$1.7M
- Hari KannanSioux Falls$913K
- Rajesh SinghSioux Falls$393K
- Ulises PescePierre$27K
- Anthony VacaSioux Falls$15K
- Harry HamlynRapid City$5K
- Mackenzie MertzSioux Falls$4K
- Georgiana NussSioux Falls$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.